医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor

2023年02月01日 PM03:30
このエントリーをはてなブックマークに追加


 

TOKYO

Shin-Nihon Public Affairs Co. (Head Office: Tokyo; President: Yasushi Kohara) today announced Mr. Yasuhisa Shiozaki as special advisor. Mr. Shiozaki is a former Chief Cabinet Secretary, and Minister of Health, Labour and Welfare, and is well versed in an extremely wide range of policy areas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230130005801/en/

Yasuhisa Shiozaki (Photo: Business Wire)

Yasuhisa Shiozaki (Photo: Business Wire)

“I will utilize my knowledge and experience I have accumulated over many years in the fields of politics and public administration to develop a variety of policy advocacy activities aimed at solving global issues,” said Shiozaki upon the appointment.

When he served as Minister of Health, Labour, and Welfare, he led to launch the Action Plan for Whole Genome Analysis, etc. to promote genomic medicine for cancer and intractable diseases, and strongly promoted data health reform. He also worked on many other policy issues, including the issue of drug resistance (AMR). After becoming a private citizen, he established the Study Group for the Promotion of Genomic Medicine in February 2022, which he continues to preside over and disseminate policy proposals for the realization of “patient-driven, patient-rewarded” genomic medicine.

“Mr. Shiozaki’s extensive experience in government and public administration will serve us well as we continue to provide a higher level of policy advocacy services, especially in the medical field to support the fostering of the genome industry as well as the raising of the overall healthcare industry toward the goal of becoming a “Health Advanced Nation”,” said Kohara.

Read Shiozaki’s full biography at https://www.y-shiozaki.or.jp/en/profile/index.html
Learn more at https://www.snpa.co.jp/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005801/en/

CONTACT

Yasushi Kohara

+81-50-6882-8582

contact_us@snpa.co.jp

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report